CR8167A - Procedimiento para la preparacion de derivados de espirobenzoacepina sustituida no peptidica - Google Patents

Procedimiento para la preparacion de derivados de espirobenzoacepina sustituida no peptidica

Info

Publication number
CR8167A
CR8167A CR8167A CR8167A CR8167A CR 8167 A CR8167 A CR 8167A CR 8167 A CR8167 A CR 8167A CR 8167 A CR8167 A CR 8167A CR 8167 A CR8167 A CR 8167A
Authority
CR
Costa Rica
Prior art keywords
preparation
derivatives
substituted
espirobenzoacepine
peptidic
Prior art date
Application number
CR8167A
Other languages
English (en)
Inventor
Deng Xiaohu
Kenney Birdella
T Liang Jimmy
Mani Neelakandha
J Villani Frank
Zhang-Plasket Fan
Zhong Hua
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR8167A publication Critical patent/CR8167A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuestos novedosos de espirobenzoazepina, procedimientos novedosos para la preparacion de derivados de espirobenzoazepina sustituidos que no son de peptido y procedimientos novedosos para la preparacion de intermediarios novedoso en la preparacion de dichos derivados; intermediarios novedoso en la preparacion de derivados espirobenzoazepina sustituidos que no son de peptidos.
CR8167A 2003-06-17 2006-01-02 Procedimiento para la preparacion de derivados de espirobenzoacepina sustituida no peptidica CR8167A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47951503P 2003-06-17 2003-06-17

Publications (1)

Publication Number Publication Date
CR8167A true CR8167A (es) 2008-09-10

Family

ID=33551892

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8167A CR8167A (es) 2003-06-17 2006-01-02 Procedimiento para la preparacion de derivados de espirobenzoacepina sustituida no peptidica

Country Status (20)

Country Link
US (2) US20040259857A1 (es)
EP (1) EP1633721A1 (es)
JP (1) JP2007516177A (es)
KR (1) KR20060023164A (es)
CN (1) CN1835926A (es)
AR (1) AR044781A1 (es)
AU (1) AU2004252135A1 (es)
BR (1) BRPI0411652A (es)
CA (1) CA2529513A1 (es)
CL (1) CL2004001508A1 (es)
CO (1) CO5650238A2 (es)
CR (1) CR8167A (es)
EA (1) EA200501829A1 (es)
HR (1) HRP20051005A2 (es)
IL (1) IL172629A0 (es)
IS (1) IS8185A (es)
NO (1) NO20060184L (es)
RS (1) RS20050933A (es)
TW (1) TW200510323A (es)
WO (1) WO2005000819A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332724T3 (es) 2003-06-17 2010-02-11 Janssen Pharmaceutica Nv Espirobenzoazepinas sustituidas.
JP2009523806A (ja) * 2006-01-20 2009-06-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （４ｒ）−１−［４−（２−クロロ−５−フルオロベンゾイル）アミノ−３−メトキシベンゾイル］−１，２，３，５−テトラヒドロ−スピロ［４ｈ−１−ベンズアゼピン−４，１’−［２］シクロペンテン］−３’−カルボン酸の新規固体形態物
AU2007299822A1 (en) * 2006-09-22 2008-03-27 Janssen Pharmaceutica N.V. Spiro benzazepines as vasopressin antagonists
PL2078022T3 (pl) * 2006-09-22 2012-04-30 Janssen Pharmaceutica Nv Spirobenzoazepiny stosowane jako antagoniści wazopresyny
AR066834A1 (es) * 2007-06-06 2009-09-16 Janssen Pharmaceutica Nv Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central.
JP2009035513A (ja) * 2007-08-02 2009-02-19 Ube Ind Ltd ４−ｎ−（メチルベンゾイル）アミノ−２−メチル安息香酸の製法
CN105609662B (zh) * 2015-12-22 2017-12-12 洪杰波 一种钙钛矿光伏材料专用的空穴传输材料的制备方法
EP4192957A4 (en) * 2020-08-07 2024-09-04 Casma Therapeutics, Inc. Trpml modulators
CN112939864B (zh) * 2021-01-29 2022-05-06 中国医科大学 螺[苯并[c]氮杂-1,1’-环己基]-3-酮类化合物
CN113735792B (zh) * 2021-09-22 2024-10-18 上海新礼泰药业有限公司 氯苯唑酸葡胺及其中间体的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW462964B (en) * 1998-05-26 2001-11-11 Sumitomo Pharma Guanidine derivatives for the treatment and prevention of disorders caused by inhibiting hyperactivity of Na/H exchange transport system and process for producing the same
HUP0301590A3 (en) * 2000-07-05 2005-01-28 Ortho Mcneil Pharm Inc Nonpeptide substituted spirobenzoazepines as vasopressin antagonists, pharmaceutical compositions containing them and their preparation
ES2332724T3 (es) * 2003-06-17 2010-02-11 Janssen Pharmaceutica Nv Espirobenzoazepinas sustituidas.

Also Published As

Publication number Publication date
WO2005000819A1 (en) 2005-01-06
BRPI0411652A (pt) 2006-08-08
CA2529513A1 (en) 2005-01-06
AU2004252135A1 (en) 2005-01-06
US20090105220A1 (en) 2009-04-23
NO20060184L (no) 2006-03-13
HRP20051005A2 (en) 2006-09-30
AR044781A1 (es) 2005-10-05
US20040259857A1 (en) 2004-12-23
CL2004001508A1 (es) 2005-05-27
CO5650238A2 (es) 2006-06-30
RS20050933A (sr) 2008-04-04
EP1633721A1 (en) 2006-03-15
JP2007516177A (ja) 2007-06-21
CN1835926A (zh) 2006-09-20
EA200501829A1 (ru) 2006-06-30
IS8185A (is) 2005-12-15
KR20060023164A (ko) 2006-03-13
TW200510323A (en) 2005-03-16
IL172629A0 (en) 2006-04-10

Similar Documents

Publication Publication Date Title
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
EA200701918A1 (ru) Белок липокалин
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
BR0215405A (pt) Composições e processos de uso de collajolie
ATE308324T1 (de) Zolpidem hemitartrat
DE69938935D1 (de) Zyklische conotoxin-peptide
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
UY27192A1 (es) Inhibidores de peptido-deformilasa
CY1105980T1 (el) Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου
ITRM20020305A1 (it) Camptotecine con anello lattonico modificato.
BRPI0514672A (pt) polipeptìdeos de fusobacterium e métodos de uso
BR0316544A (pt) Compostos calcilìticos
DE60114567D1 (de) Selektive acylierung von a82846-glycopeptid-analoge
ITTO20030264A1 (it) Anello.
ATE433953T1 (de) Peptiddeformylaseinhibitoren
HN2002000177A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso.
ES1048957Y (es) Linterna de reclamo para la pesca.
ITPN20020071A1 (it) Procedimento per la fabbricazione di mobili.
ES1053021Y (es) Disposicion mejorada para la ventilacion de naves.
ES1048243Y (es) Maquina para la prepoda de arboles.
ITTO20020290A1 (it) Anello
CY1115144T1 (el) Παραγωγα του uk-2a
ECSP003536A (es) Derivados de rufomicina utiles como antibioticos
ITMI20011735A1 (it) Procedimento per la preparazione del 14beta-idrossi-baccatina iii-1, 14 -carbonato

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)